Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR443726
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
SAR443726 is an investigational bispecific nanobody (VHH) developed by Sanofi that simultaneously targets interleukin-13 (IL-13) and OX40 ligand (OX40L). It was designed to treat type 2 inflammatory diseases, primarily atopic dermatitis, by inhibiting two distinct pathways: IL-13, a central mediator of Th2-driven inflammation, and OX40L, a co-stimulatory molecule that promotes T-cell activation and survival. The drug was evaluated in a Phase 1 first-in-human study to assess safety, tolerability, and pharmacokinetics in healthy volunteers and patients with moderate-to-severe atopic dermatitis. In 2023, Sanofi discontinued the development of SAR443726 based on its clinical profile and broader portfolio prioritization.
02
Targets
IL13RA2 (Interleukin-13 receptor subunit alpha 2)TNFSF4 (Tumor necrosis factor ligand superfamily member 4)IL-13 (Interleukin-13)
Beyond the preview
Go deeper on SAR443726.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR443726.